KPV - Educational materials

KPV is a naturally occurring peptide derived from alpha-melanocyte stimulating hormone (alpha-MSH). It consists of three amino acids: lysine, proline and valine. Derived from alpha-melanocyte stimulating hormone (alpha-MSH), KPV has potent anti-inflammatory properties that can significantly reduce inflammation by modulating the immune response.

The article examines background, mechanism of action, dosage, side effects, research citations, case studies and recommendations for potential uses.

Peptides, such as oxytocin, endorphins, KPV, enkephalins and others, are short chains of amino acids, containing less than 50 amino acids. They occur naturally in nature and play various roles in biological systems, such as as hormones, neurotransmitters and signaling molecules. The discovery of peptides dates back to the early 20th century, when scientists began identifying and isolating small protein fragments from a variety of sources.

One of the earliest peptides discovered was oxytocin, a hormone isolated from the posterior pituitary gland in 1906. In the following years, scientists continued to identify and study new peptides, including endorphins, which were discovered in the 1970s. Other important peptides discovered during this time included enkephalins and substance P. Advances in modern peptide synthesis and sequencing techniques have led to significant progress in this area of research. As a result, researchers have identified several tripeptides related to alpha-melanocyte stimulating hormone (α-MSH). These peptides include KPV (lysine, proline, valine) and AGRP (Agouti-related protein), as well as synthetic tripeptides such as MT-II (Melanotan II) and PT-141 (Bremelanotide). They have shown potential therapeutic applications in various areas, including anti-inflammatory agents, antimicrobial agents, cancer therapies and treatment of neurological disorders.

Potential health benefits of KPV tripeptide

KPV tripeptide needs to be studied more thoroughly in humans. However, based on animal and laboratory studies, it has the following potential health benefits:

• KPV tripeptide has been found to have potent anti-inflammatory and antipyretic properties, which can help reduce pain, swelling and fever associated with various chronic health conditions. KPV tripeptide works by inhibiting the production of inflammatory cytokines and signaling pathways responsible for inflammation and fever;
• In addition to its anti-inflammatory effects, KPV tripeptide has also been found to have significant benefits for gastrointestinal health. It may help improve intestinal homeostasis, modulate intestinal flora and alleviate symptoms associated with inflammatory bowel disease (IBD), ulcerative colitis (UC) and irritable bowel syndrome (IBS);
• KPV tripeptide has been shown to have a positive effect on wound healing due to its strong anti-inflammatory properties. It can accelerate the wound healing process, and unlike other treatments, it does not cause skin pigmentation. In addition, the immunostimulating effect of KPV tripeptide can reduce the risk of infection during the wound regeneration process;
• The antimicrobial properties of KPV tripeptide also make it a potential agent for the prevention and treatment of various infectious diseases caused by microbes such as Staphylococcus aureus (Staphylococcus aureus) and Candida albicans. These microbes are responsible for many infections, and the antibacterial properties of KPV tripeptide may help prevent and treat them;
• KPV tripeptide has also been found to have beneficial effects on skin health. Its anti-inflammatory effects can improve skin conditions such as inflammation, irritation and allergic contact dermatitis. In addition, its antibacterial properties can help prevent and treat skin infections;
• In addition, KPV tripeptide has been found to have potential benefits for brain health. It can protect the integrity of neurons from inflammatory mediators, thereby preventing neuroinflammation and other neurodegenerative conditions. KPV tripeptide has many potential health benefits, making it a promising compound for future research and development.

KPV: Mechanism of action

KPV works by suppressing the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, which are responsible for the inflammatory response in the body. Both laboratory and animal studies have confirmed that KPV reduces the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and nitric oxide (NO), and suppresses the activation of nuclear transcription factor NF kappa B (NF-κB) in human keratinocytes and monocytoid cells. In addition, it was found to have similar effects on suppressing NF-κB activation as Melanotropin. KPV's stereoisomer, KdPV, was also shown to suppress LPS-induced NF-κB activation in rat alveolar cells. Other related peptides and stereoisomers show weaker anti-inflammatory activity than KPV.

KPV peptide research

KPV and inflammatory bowel disease (IBD)

During animal studies, the melanocortin-derived tripeptide KPV was shown to have significant anti-inflammatory effects in two models of colitis, DSS and CD45RB (hi). In the DSS model, KPV treatment resulted in earlier recovery, significant weight gain, and reduced inflammatory infiltration and myeloperoxidase (MPO) activity in colonic tissue. KPV treatment also led to recovery, weight regain and reduced inflammatory changes in CD45RB colitis (hi). This study suggested that KPV may be a promising therapeutic option for the treatment of inflammatory bowel disease (IBD), and the effects of KPV appear to be partially independent of MC1R signaling [1].

A recent study found that KPV, has anti-inflammatory properties that may benefit the gut. The study found that the protein transporter hPepT1 can transport KPV, allowing it to enter intestinal epithelial cells and immune cells. Once inside, KPV inhibits the activation of NF-κB and MAPK pathways, which are important signaling pathways. KPV also reduces the secretion of pro-inflammatory cytokines. The study conducted experiments on mice, where oral administration of KPV was found to reduce colitis and inflammation. The study also suggests that hPepT1 plays an important role in mediating the anti-inflammatory effects of KPV, and that immune cells can also reduce inflammation through KPV. Overall, these studies highlight the potential of KPV as a treatment for inflammatory bowel disease (IBD) [2].

In the latest study, researchers engineered nanoparticles to transport the anti-inflammatory tripeptide KPV into the colon to evaluate its therapeutic efficacy in treating colitis in mice. Both in vitro and in vivo experiments showed that NP-KPV reduced inflammatory responses and shielded mice from inflammatory and histological parameters. These results suggest that NPs may serve as a drug delivery system that can overcome physiological barriers and deliver anti-inflammatory agents, such as KPV, to inflammatory areas. This could be a novel and innovative treatment for IBD [3].

KPV and inflammatory, autoimmune and allergic diseases

In a mouse model of contact hypersensitivity, alpha-MSH and KPV inhibited sensitization and elicitation of the immune response and induced hapten-specific tolerance. These results suggest that KPV and related peptides may potentially represent a future therapeutic approach for various inflammatory, autoimmune and allergic diseases [4].

KPV and ulcerative colitis

According to animal studies, a hydrogel known as PMSP derived from a certain type of acid was an effective carrier of KPV, for the treatment of ulcerative colitis (UC). PMSP was able to adhere to the inflamed colon, preserving the bioactivity of KPV. Moreover, it also provided better stability even at high temperatures. Rats with ulcerative colitis treated with PMSP-KPV had fewer symptoms and showed restoration of the colonic epithelial barrier. In addition, PMSP-KPV had a positive effect on the intestinal flora by increasing the abundance of beneficial microorganisms [5].

Another study found that KPV/SH-PGA hydrogel was effective in relieving symptoms of colitis, promoting colonic regeneration and reducing the expression of pro-inflammatory cytokines. It was concluded that KPV/SH-PGA hydrogel may be a promising strategy for the treatment of ulcerative colitis [6].

In an animal study, polymeric nanoparticles (NPs) loaded with KPV showed an effect of accelerating mucosal healing and relieving inflammation without toxicity to intestinal cells. When encapsulated in a hydrogel and administered orally to mice, the HA-KPV-NP/hydrogel system showed better therapeutic efficacy in the treatment of ulcerative colitis than the KPV-NP/hydrogel system alone, indicating the potential of targeted delivery of KPV in the treatment of UC [7].

KPV and cancer

The animal study reported that mice with overexpression of the intestinal protein transporter 1 (hPepT1) gene had larger tumors and increased inflammation. In contrast, mice with hPepT1 deletion had reduced tumor size and inflammation. In addition, increased hPepT1 expression was observed in human colon tissue samples from colon cancer patients, suggesting that hPepT1 may be a potential treatment for colon cancer. The study also showed that the anti-inflammatory tripeptide transported by hPepT1 KPV prevented tumor formation in wild-type mice, but had no effect in mice with hPepT1 deletion. These results suggest that KPV could be used to treat colorectal cancer through its transport by hPepT1 [8].

KPV and pneumonia (asthma)

The researchers studied the effects of KPV and γ-MSH, a melanocortin receptor agonist, on suppressing inflammation in human airway bronchial epithelium. They found that both KPV and γ-MSH could inhibit NFκB signaling, matrix metalloproteinase-9 activity, and IL8 and eotaxin secretion in a dose-dependent manner. KPV suppressed nuclear import of p65RelA. Melanocortin peptides such as KPV have been found to target airway inflammation in lung diseases [9].

Synthetic KPV and HIV-infected cells

One study examined the effects of alpha-MSH and its tripeptide KPV on HIV expression in infected cells. The study found that HIV-infected U1 cells produced alpha-MSH, which inhibits HIV expression through the alpha-MSH receptor 1 (MC1R). Synthetic alpha-MSH and KPV also reduced HIV replication by inhibiting nuclear kappa factor B activation at the transcriptional level. These results suggest that higher concentrations of synthetic KPV may be more effective in reducing HIV expression in infected cells [10].

KPV and neuroinflammation

A neuro-immunomodulatory peptide, alpha-MSH modulates the production and action of pro-inflammatory cytokines in inflammatory cells in the peripheral and central nervous system. Research reports that alpha-MSH [11-13] KPV, a fragment of alpha-MSH, also modulates inflammation through direct actions on peripheral cells, actions on inflammatory cells within the brain, and descending neuronal anti-inflammatory pathways that control inflammation in peripheral tissues [11].

KPV vs antimicrobial activity

Several studies have shown that KPV, the K-terminal tripeptide, is essential for its direct antimicrobial efficacy and has antimicrobial potential. In addition, (CKPV) 2, a dimer of the peptide, was shown to have antifungal activity against Candida vaginitis both in vitro and in vivo. Furthermore, the C-terminal tripeptide of α-MSH, which includes KPV, was found to have antimicrobial activity against E. coli, and α-MSH was found to have antimicrobial activity against both planktonic and biofilm phenotypes of S. aureus strains, regardless of their sensitivity to methicillin [12].

In vitro studies have shown that (CKPV) 2 exhibits antimicrobial activity against Gram-positive and Gram-negative bacteria, as well as against several fungal strains, including Candida albicans. The antimicrobial activity of (CKPV) 2 is believed to be due to its ability to disrupt the cell membrane of microorganisms, leading to cell death [12, 13]. Alpha-MSH and its fragment KPV have shown inhibitory activity against Staphylococcus aureus, a gram-positive bacteria, and Candida albicans, a yeast, in tests of their antimicrobial activity [12, 13].

KPV and wound healing

It was discovered that KPV promotes corneal epithelial wound healing in rabbits and can bind to nitric oxide (NO) in corneal tissue. After topical administration of KPV, significantly more small corneal epithelial defects and complete re-epithelialization were noted compared to the control group. The potential therapeutic effect of KPV was blocked by the use of L-NAME, a nitric oxide synthase inhibitor. This particular in vitro study indicated that KPV increased cell viability in rabbit corneal epithelial cells [14].

KPV and fever

The importance of the 11-13 amino acid sequence in α-MSH for its antipyretic effect was determined. Lysine, proline, valine (KPV) was administered to febrile rabbits both centrally and peripherally. The results showed that KPV reduced fever after both central and peripheral administration. This indicated that the 11-13 sequence is part of the α-MSH communication sequence for its antipyretic activity. However, KPV was less potent than the parent molecule, suggesting that other parts of the molecule are necessary for the full antipyretic effect [15].

Application route

Limited data are available from human studies indicating the appropriate dosage and route of administration of KPV, as most studies of this tripeptide have been conducted in rodents.

Based on available data, KPV can be effectively administered by topical cream, injection, transdermally or orally via capsules, or spray. The most appropriate method of administration depends on the specific area to be affected. In the oral form, KPV can help relieve intestinal problems. The injectable form of KPV is usually administered for a systemic anti-inflammatory effect.

Side effects of KPV tripeptide

According to various animal studies, KPV was generally well tolerated. However, as with any supplement or drug, there are potential side effects in the form of gastrointestinal upset and hypersensitivity to KPV.

It should be noted that more research is needed on the effects and harm of KPV in humans, and caution should be exercised when using this peptide.

It is recommended to start with a low dose and gradually increase it as tolerated while monitoring for potential side effects. It is not recommended to take KPV if the recipient is breastfeeding, pregnant or planning to become pregnant.

Although KPV has shown promising potential health benefits in animal studies, more research is needed to determine its efficacy and safety in humans.

Dosage of KPV tripeptide

The dosage of KPV as a supplement is not specified, as human studies are lacking. For research purposes, the following is a sample protocol for investigators wishing to administer KPV to observe its effects on reducing inflammation and accelerating wound healing and skin irritation [15].

Daily dosage: Based on animal studies, administer 200-400mcg KPV by subcutaneous injection/parenterally.

Frequency of dosage: Administer daily.

Duration: Serve until the desired result is achieved.

If skin irritation occurs or worsens, KPV tripeptide should be discontinued. One vial of KPV containing 5 mg is sufficient for a 25-day treatment period according to this protocol.

Note that this is only an example protocol. The appropriate dose and timing of KPV administration may vary depending on the specific study objectives and subjects. It is also important to consult with your healthcare provider and follow all applicable guidelines and ethical regulations for conducting research with human subjects.

Summary

Based on data from various studies, the KPV peptide has potential applications in the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC) and other inflammatory, autoimmune and allergic diseases. KPV exhibits anti-inflammatory properties that may benefit the gut, nerves and lungs. It can inhibit the activation of inflammatory signaling pathways and reduce the secretion of pro-inflammatory cytokines. KPV can be transported to sites of inflammation using drug delivery systems such as nanoparticles and hydrogels. KPV was also found to have a unique anti-inflammatory effect, which may occur through inhibition of IL-1beta function. In addition, KPV has potential in the treatment of cancer, as its action binds to the hPepT1 protein, which is overexpressed in colorectal cancer patients.

Moreover, KPV may support neuronal health, exhibit antimicrobial activity and promote wound healing. Some studies suggest that KPV may have antipyretic properties, potentially helping to reduce fever. However, it is important to note that the available research on KPV is still limited and more is needed to fully understand its potential benefits and any associated risks.

Disclaimer

This article was written for educational purposes and is intended to raise awareness of the substance being discussed. It is important to note that the substance discussed is a substance, not a specific product. The information contained in the text is based on available scientific research and is not intended to serve as medical advice or promote self-medication. The reader should consult any health and treatment decisions with a qualified health professional.

Sources:

1. Kannengiesser, K., Maaser, C., Heidemann, J., Luegering, A., Ross, M., Brzoska, T., Bohm, M., Luger, T. A., Domschke, W., & Kucharzik, T. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory bowel diseases, 14(3), 324-331. https://doi.org/10.1002/ibd.20334
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008 Jan;134(1):166-78. doi: 10.1053/j.gastro.2007.10.026. epub 2007 Oct 17. PMID: 18061177; PMCID: PMC2431115.
3. Laroui, H., Dalmasso, G., Nguyen, H. T., Yan, Y., Sitaraman, S. V., & Merlin, D. (2010). Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology, 138(3), 843-53.e532. https://doi.org/10.1053/j.gastro.2009.11.003
4. Luger, T. A., Scholzen, T. E., Brzoska, T., & Böhm, M. (2003). New insights into the functions of alpha-MSH and related peptides in the immune system. Annals of the New York Academy of Sciences, 994, 133-140. https://doi.org/10.1111/j.1749-6632.2003.tb03172.x
5. Zhao, Y., Xue, P., Lin, G., Tong, M., Yang, J., Zhang, Y., Ran, K., Zhuge, D., Yao, Q., & Xu, H. (2022). A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta biomaterialia, 143, 233-252. https://doi.org/10.1016/j.actbio.2022.02.039
6. Sun, J., Xue, P., Liu, J., Huang, L., Lin, G., Ran, K., Yang, J., Lu, C., Zhao, Y. Z., & Xu, H. L. (2021). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS biomaterials science & engineering, 7(10), 4859-4869. https://doi.org/10.1021/acsbiomaterials.1c00792
7. Xiao, B., Xu, Z., Viennois, E., Zhang, Y., Zhang, Z., Zhang, M., Han, M. K., Kang, Y., & Merlin, D. (2017). Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular therapy: the journal of the American Society of Gene Therapy, 25(7), 1628-1640. https://doi.org/10.1016/j.ymthe.2016.11.020
8. Viennois, E., Ingersoll, S. A., Ayyadurai, S., Zhao, Y., Wang, L., Zhang, M., Han, M. K., Garg, P., Xiao, B., & Merlin, D. (2016). Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model. Cellular and molecular gastroenterology and hepatology, 2(3), 340-357. https://doi.org/10.1016/j.jcmgh.2016.01.006
9. Land S. C. (2012). Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International journal of physiology, pathophysiology and pharmacology, 4(2), 59-73.
10. Barcellini, W., Colombo, G., La Maestra, L., Clerici, G., Garofalo, L., Brini, A. T., Lipton, J. M., & Catania, A. (2000). Alpha-melanocyte-stimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. Journal of leukocyte biology, 68(5), 693-699.
11. Ichiyama, T., Sato, S., Okada, K., Catania, A., & Lipton, J. M. (2000). The neuroimmunomodulatory peptide alpha-MSH. Annals of the New York Academy of Sciences, 917, 221-226. https://doi.org/10.1111/j.1749-6632.2000.tb05386.x
12. Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610. doi: 10.1155/2014/874610. epub 2014 Jul 23. PMID: 25140322; PMCID: PMC4130143.
13. Catania, A., Cutuli, M., Garofalo, L., Carlin, A., Airaghi, L., Barcellini, W., & Lipton, J. M. (2000). The neuropeptide alpha-MSH in host defense. Annals of the New York Academy of Sciences, 917, 227-231. https://doi.org/10.1111/j.1749-6632.2000.tb05387.x
14. Bonfiglio, V., Camillieri, G., Avitabile, T., Leggio, G. M., & Drago, F. (2006). Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Experimental eye research, 83(6), 1366-1372. https://doi.org/10.1016/j.exer.2006.07.014
15. Brzoska, Thomas; Luger, Thomas A.; Maaser, Christian; Abels, Christoph; Böhm, Markus (2008). α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Anti-inflammatory and Protective Effects in Vitro and in Vivo , and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. Endocrine Reviews, 29(5), 581-602. doi:10.1210/er.2007-0027